Presentation is loading. Please wait.

Presentation is loading. Please wait.

Micheline Ho Therapeutic Products Directorate October 19, 2004

Similar presentations


Presentation on theme: "Micheline Ho Therapeutic Products Directorate October 19, 2004"— Presentation transcript:

1 Micheline Ho Therapeutic Products Directorate October 19, 2004
Overview of the Canadian Federal Drug Review Process Pharmaceutical Marketing Club of Quebec Education Day Seminar Micheline Ho Therapeutic Products Directorate October 19, 2004

2 Responsibilities for Drugs
Federal Regulates the safety, efficacy and quality of drugs Ensures patent linkage (Health Products & Foods Branch) Controls the price of patented medicines (Patented Medicines Prices Review Board) Coordination and leadership on FPT pharmaceutical issues Provincial Delivery of healthcare Practice of Medicine/Pharmacy Reimbursement issues Drug Formularies

3 Federal Legislation and Guidance for Drugs
Food and Drugs Act and Regulations Governs the safety, effectiveness and quality of drugs and medical devices available to Canadians. Patented Medicines (NOC) linkage Regulation Financial Administration Act (fees for review-cost recovery) Access to Information and Privacy Act Controlled Drugs and Substances Act (governs narcotic & controlled drugs) Policies and Guidelines (including International Guidelines - ICH) in support of the Acts and Regulations

4 Health Canada

5 Health Products and Food Branch

6 Therapeutic Products Directorate
Effective April 1, 2002

7 Health Products and Food Branch (HPFB) Responsibilities for Drugs
Therapeutic Products Directorate (TPD) Responsible for evaluating the safety, effectiveness and quality of pharmaceutical drugs and medical devices available to Canadians. Similar to CDER in U.S. – F.D.A. Biologics and Genetic Therapies Directorate (BGTD) Responsible for evaluating the safety, effectiveness and quality of biological and radiopharmaceutical drugs, as well as blood and blood products, viral and bacterial vaccines, genetic therapeutic products, tissues, organs and xenografts. Similar to CBER in U.S. – F.D.A.

8 Health Products and Food Branch (HPFB) Responsibilities for Human Drugs - cont’d
HPFB Inspectorate – Compliance & Enforcement Responsible for delivery of inspections and investigations, and for most establishment licensing and related laboratory analysis functions. Marketed Health Products Directorate (MHPD) Responsible for post-market assessment and surveillance of pharmaceutical and biological drugs, medical devices, natural health products, radio-pharmaceuticals.

9 Product Types Regulated as “Drugs”
Pharmaceuticals (prescription, non-prescription, brand name, generic) Biological drugs (vaccines, recombinant drugs, blood products) Radiopharmaceuticals Natural Health Products Homeopathic products Traditional herbal medicines Other Herbals Disinfectants for use on medical instruments, hospital and food preparation surfaces Veterinary Drugs

10 Life of a New Drug Research
Create/Isolate Chemicals Tissue/Culture More Specific animal (14,000 tested to get one as marketable) small animals testing and in vitro tests (e.g. carcinogenicity, reproductive studies) Human Testing Special Access Program (SAP) (Clinical Trial) (emergency release) HC approval required (Food & Drug Act & Regulations 30 day default) Post Market Surveillance Provincial Formulary Decisions All testing is done, drug company completes analysis of data, prepares New Drug PMPRB Submission (NDS) (price controls) HC Review Decision

11 Drugs Sold in Canada All drugs sold in Canada must be approved by Health Canada. These include but are not limited to the following: drugs imported from other countries; drugs manufactured in Canada; Division 8 / C (DIN) New drug

12 New Drug Approval Process

13 Submission Processing – more details

14 Priority Review ... for a drug submission for a serious, life threatening or severely debilitating disease or condition for which there is substantial clinical evidence that the drug provides: effective treatment/prevention/diagnosis of a disease or condition for which no drug is presently marketed in Canada… pdf

15 Performance Targets The type of data package (safety, efficacy, quality) submitted and whether or not it is accepted for priority review determines the performance target Examples: Processing days* Screening days* NDS – Review : priority days* non-priority days* ANDS - Review : days* * Calendar days

16 Performance Reporting
Drug submission performance is reported quarterly and annually Reports are posted on our website:

17 Drug Identification Numbers (DINs) and Notices of Compliance (NOC)
DINS are issued to all drugs approved for marketing in Canada. (8 digit number generated by DPD) Must appear on the label Notification of first sale NOC are issued to all new drugs that are approved.

18 DIN / NOC / NOC-C DINA Authorized labels Prescribing Information NOC
NOC Letter Product Monograph Labels NOC-C NOC Letter Product Monograph Labels Letter of Undertaking

19 NOC-C For: Serious, life-threatening Severely debilitating conditions, or Significant improvement in efficacy Significant decrease in side-effects when no marketed treatment to adequately manage the condition

20 NOC-C (continued) May provide earlier access
Physicians and patients to be aware Letter of Undertaking Clinical studies ADR monitoring Distribution / Advertising conditions Pre-clearance by PAAB

21 Therapeutic Access Strategy (TAS)
Key Business Transformation Strategy Speech from the Throne As part of its focus on Smart Regulation, the government …. (will) speed up the regulatory process for drug approvals to ensure Canadians have faster access to the safe drugs they need.” Budget Provide $190 million over 5 years “to improve the timeliness of Health Canada’s regulatory processes with respect to human drugs – while preserving the principle that safety is of paramount concern.”

22 Health Canada’s Response: The Therapeutics Access Strategy
In the near term, improve regulatory performance around timeliness and transparency, benchmarked against leading international practices

23 The Initiatives Project Management Good Review Practices
International Cooperation Transparency E-Review Regulatory Policy Expert Advisory Capacity

24 Post Market Roles and Activities
Legislated responsibilities, ‘Duty of Care’ regarding safety of new drugs Activities Monitor and collect adverse drug reaction and medication incident data and communicate these to health professionals and public (e.g. Advisories for therapeutic products, Canadian Adverse Drug Reaction Newsletter, Health_Prod_Info) Review and analyze safety data Conduct risk/benefit assessments of marketed products Overview of regulatory advertising activities

25 Strengthening Post-Market Safety of New Drugs
Measures will include: Moving from reactive to proactive and preventative measures Expanding network of Regional Adverse Reaction Centers Launching investigations and requiring manufacturers to conduct post-approval clinical trials More timely and accurate advice to health care professionals and the public Outcomes: Will reduce risks to Canadians from preventable adverse drug events

26 International Harmonization
HPFB has been very active in helping develop and implement international standards for the registration of new drugs. HPFB has contributed significantly to the development of over 45 harmonized technical guidelines. Canada is the only observer country to the International Conference on Harmonization (ICH) and is committed to implementing finalized ICH guidelines and standards including the Common Technical Document (CTD).

27 Drug Submissions Received Annually (approx.) (TPD & BGTD)
Total: 4,400 per year 80 – NDS (New Drug Submission) 35 for new active substances 170 – SNDS (Supplement to NDS) 80 – ANDS (Abbreviated New Drug Submission) 10 – SANDS (Supplement to ANDS) 800 – NC (Notifiable Change)

28 Drug Submissions Received Annually (approx.) (TPD & BGTD) – cont’d
1700 – DINA (Drug Identification Number Application) 360 – Administrative Change Submissions Change in manufacturer’s name and/or product name; cross-reference submissions 1200 – Clinical Trial Applications (previously INDs – Investigational New Drug Submissions)

29 Drugs Marketed in Canada
22,000 (approx.) Human Drug Products 6,000 Prescription 9,000 Non-Prescription 6,000 Homeopathics 1,000 Controlled Drugs, Narcotics & Biologics 1,450 (approx.) Veterinary Drug Products

30 TPD Websites / Contact Points
TPD Main Website: SIPD – Marketing Status (Drug Product Database [DPD]): NOC Database: Food and Drugs Act and Regulations Guidance Documents, Policies, Templates, Forms: Specific Product Information – RPM’s

31 Continuous Balancing Act
Drug submission review performance is impacted by the many other issues and challenges which we strive to keep in balance: advancements in science and technology timeliness vs. ensuring safety / efficacy adhering to strict regulations/policies and being flexible and reasonable participating in an international community while respecting our domestic environment

32 Lexicon ADR Adverse Drug Reaction ANDS Abbreviated New Drug Submission
BGTD Biologic and Genetic Therapies Directorate CDER Center for Drug Evaluation & Research DIN Drug Identification Number (an 8-digit number that all drugs in Canada must have) DINA Drug Identification Number Application DPD Drug Product Database FDA United States Food and Drug Administration

33 Lexicon- cont’d FPT Federal / Provincial / Territorial
ICH International Conference on Harmonization IND Investigational New Drug Submission MHPD Marketed Health Products Directorate NC Notifiable Change NDS New Drug Submission NOC Notice of Compliance (an approval letter to market a product in Canada) NOC-C Notice of Compliance with Conditions

34 Lexicon - cont’d RPM Regulatory Project Manager
SRPM Senior Regulatory Project Manager PM Product Monograph SANDS Supplemental Abbreviated New Drug Submission SIPD Submission Information Policy Division SNDS Supplemental New Drug Submission TAS Therapeutic Access Strategy


Download ppt "Micheline Ho Therapeutic Products Directorate October 19, 2004"

Similar presentations


Ads by Google